Law360 (November 20, 2008, 12:00 AM EST) -- After several years of hard-fought litigation, Abbott Laboratories has agreed to pay $184 million to settle antitrust claims by rival pharmaceutical companies, drug stores and other purchasers that the company profited by unfairly blocking a generic version of the blockbuster cholesterol drug TriCor from the market.
The settlement resolves allegations by competitors Teva Pharmaceuticals and Impax Laboratories Inc. that Abbott conspired with its French partner Fournier Industrie et Sante to launch frivolous lawsuits to fence off the market and prevent competition for TriCor.
Abbott and Fournier filed more than 10 patent lawsuits — all of which were later dismissed or lost...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!